LIVZON PHARMA Schedules 23 April 2026 Board Meeting to Approve Q1 Results

Bulletin Express

04/08

Livzon Pharmaceutical Group Inc. (LIVZON PHARMA) announced that its Board of Directors will convene on 23 April 2026 to review and approve the unaudited consolidated results for the three months ended 31 March 2026. Additional routine corporate matters may also be addressed during the session.

The notification, released from Zhuhai on 8 April 2026, lists the current Board composition: • Executive Director: Tang Yanggang (Vice Chairman) • Non-Executive Directors: Zhu Baoguo (Chairman), Lin Nanqi, Qiu Qingfeng • Employee Representative Director: Ran Yongmei • Independent Non-Executive Directors: Bai Hua, Luo Huiyuan, Cui Lijie, Wang Zhiyao

Investors and stakeholders can expect the company to release its first-quarter 2026 financial figures following the Board’s deliberations on the scheduled date.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1182294159"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1182294159\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1182294159?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-08 17:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1182294159","market":"hk","top_or_hot":-1,"title":"LIVZON PHARMA Schedules 23 April 2026 Board Meeting to Approve Q1 Results","media":"Bulletin Express","content":"<p>Livzon Pharmaceutical Group Inc. (LIVZON PHARMA) announced that its Board of Directors will convene on 23 April 2026 to review and approve the unaudited consolidated results for the three months ended 31 March 2026. Additional routine corporate matters may also be addressed during the session.</p>\n<p>The notification, released from Zhuhai on 8 April 2026, lists the current Board composition:\n• Executive Director: Tang Yanggang (Vice Chairman)  \n• Non-Executive Directors: Zhu Baoguo (Chairman), Lin Nanqi, Qiu Qingfeng  \n• Employee Representative Director: Ran Yongmei  \n• Independent Non-Executive Directors: Bai Hua, Luo Huiyuan, Cui Lijie, Wang Zhiyao</p>\n<p>Investors and stakeholders can expect the company to release its first-quarter 2026 financial figures following the Board’s deliberations on the scheduled date.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LIVZON PHARMA Schedules 23 April 2026 Board Meeting to Approve Q1 Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLIVZON PHARMA Schedules 23 April 2026 Board Meeting to Approve Q1 Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-08 17:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Livzon Pharmaceutical Group Inc. (LIVZON PHARMA) announced that its Board of Directors will convene on 23 April 2026 to review and approve the unaudited consolidated results for the three months ended 31 March 2026. Additional routine corporate matters may also be addressed during the session.</p>\n<p>The notification, released from Zhuhai on 8 April 2026, lists the current Board composition:\n• Executive Director: Tang Yanggang (Vice Chairman)  \n• Non-Executive Directors: Zhu Baoguo (Chairman), Lin Nanqi, Qiu Qingfeng  \n• Employee Representative Director: Ran Yongmei  \n• Independent Non-Executive Directors: Bai Hua, Luo Huiyuan, Cui Lijie, Wang Zhiyao</p>\n<p>Investors and stakeholders can expect the company to release its first-quarter 2026 financial figures following the Board’s deliberations on the scheduled date.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01513","symbol_name":"丽珠医药","start_time":0,"source_url":"","article_id":"1182294159","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1182294159","pubTimestamp":1775638900,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Livzon Pharmaceutical Group Inc. (LIVZON PHARMA) announced that its Board of Directors will convene on 23 April 2026 to review and approve the unaudited consolidated results for the three months...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01513":"丽珠医药"},"translate_title":"丽珠医药定于2026年4月23日召开董事会批准第一季度业绩","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01513":1},"content_text":"Livzon Pharmaceutical Group Inc. (LIVZON PHARMA) announced that its Board of Directors will convene on 23 April 2026 to review and approve the unaudited consolidated results for the three months ended 31 March 2026. Additional routine corporate matters may also be addressed during the session.\nThe notification, released from Zhuhai on 8 April 2026, lists the current Board composition:\n• Executive Director: Tang Yanggang (Vice Chairman)  \n• Non-Executive Directors: Zhu Baoguo (Chairman), Lin Nanqi, Qiu Qingfeng  \n• Employee Representative Director: Ran Yongmei  \n• Independent Non-Executive Directors: Bai Hua, Luo Huiyuan, Cui Lijie, Wang Zhiyao\nInvestors and stakeholders can expect the company to release its first-quarter 2026 financial figures following the Board’s deliberations on the scheduled date.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"conferences,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}